Theracryf Plc (AIM:TCF)

Theracryf Income Statement

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	-	0.4	0.44	-	0.19
Revenue Growth (YoY)	-	-10.41%	-	-	-
Cost of Revenue	2.12	3.95	5.53	3.18	3.39
Gross Profit	-2.12	-3.55	-5.09	-3.18	-3.2
Selling, General & Admin	-	0.02	0.01	0.01	0.02
Operating Expenses	-	0.02	0.01	0.01	0.02
Operating Income	-2.12	-3.57	-5.1	-3.19	-3.21
Interest & Investment Income	0.01	-	0.1	0.02	-
Other Non Operating Income (Expenses)	0.03	-	-	-	-
EBT Excluding Unusual Items	-2.09	-3.57	-5.01	-3.17	-3.21
Pretax Income	-2.09	-3.57	-5.01	-3.17	-3.21
Income Tax Expense	-0.14	-0.43	-0.96	-0.44	-0.54
Net Income	-1.94	-3.14	-4.04	-2.73	-2.67
Net Income to Common	-1.94	-3.14	-4.04	-2.73	-2.67
Shares Outstanding (Basic)	538	275	275	275	147
Shares Outstanding (Diluted)	538	275	275	275	147
Shares Change (YoY)	95.83%	-	-	86.97%	13.69%
EPS (Basic)	-0.00	-0.01	-0.01	-0.01	-0.02
EPS (Diluted)	-0.00	-0.01	-0.01	-0.01	-0.02
Free Cash Flow	-2.37	-3	-4.13	-2.59	-2.93
Free Cash Flow Per Share	-0.00	-0.01	-0.01	-0.01	-0.02
Operating Margin	-	-900.51%	-1154.75%	-	-1656.19%
Profit Margin	-	-792.17%	-914.71%	-	-1378.35%
Free Cash Flow Margin	-	-756.57%	-933.94%	-	-1510.83%
EBITDA	-2.06	-3.56	-5.09	-3.18	-3.2
D&A For EBITDA	0.07	0.01	0.01	0.02	0.02
EBIT	-2.12	-3.57	-5.1	-3.19	-3.21

Updated Nov 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.